FDMT Q1 2024 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$28,000-90.6% YoY

Gross Profit

-$28M-99435.7% margin

Operating Income

-$38M-136200.0% margin

Net Income

-$32M-115717.9% margin

EPS (Diluted)

$-0.66

QoQ Revenue Growth

+247.4%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$30M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$630M

Total Liabilities

$29M

Stockholders' Equity

$601M

Cash & Equivalents

$276M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28,000	$298,000	-90.6%
Gross Profit	-$28M	-$22M	-25.9%
Operating Income	-$38M	-$30M	-26.7%
Net Income	-$32M	-$29M	-13.0%

Revenue Segments

Collaboration And License Revenue

$28,000100%

Geographic Segments

UNITED STATES

$28,000100%